Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.

Public health genomics - 1 Jan 2013

Shkedi-Rafid S, Ofer-Bialer G, Meiner V, Calderon-Margalit R

Abstract excerpt

AIMS: Advances in genomics may eventually lead to genetic susceptibility screening of the general population, regardless of a personal or familial history of the disease in question. Yet, little is known about clinicians' attitudes toward such programs. We explored attitudes of family practitioners, medical geneticists and genetic counselors toward genetic screening of the general Ashkenazi-Jewish population for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Attitude of Health Personnel
Share to Employment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Founder Effect

Share to Health Knowledge, Attitudes, Practice

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Prejudice

Source

Identifiers

PMID: 23816973
DOI: 10.1159/000351592

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.PMID 23816973Read ↗

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.Semantic proximity Read ↗

BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.Semantic proximity Read ↗

Perceptions of genetic testing for cancer predisposition among Ashkenazi Jewish women.Semantic proximity Read ↗

Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.Semantic proximity Read ↗

A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing.Semantic proximity Read ↗

Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Population-based Genetic Testing for Precision Prevention.Semantic proximity Read ↗

Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.Semantic proximity Read ↗

Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.Semantic proximity Read ↗

Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.